ASH 2020 | Belantamab mafodotin: ocular toxicity
Sagar Lonial
• 2 Dec 2020
With reference to the DREAMM-2 (NCT03525678) trial, Sagar Lonial, MD, Winship Cancer Institute of Emory University, Atlanta, GA, delineates the potential for ocular toxicities in multiple myeloma patients treated with antibody-drug conjugate belantamab mafodotin. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Sagar Lonial, MD, has done consultancy work for Takeda, Celgene, BMS, Janssen, GSK, Abbvie, Novartis and Janssen; and has been a member of a board of directors for TG Therapeutics.
